1-(4-(5-amino-6-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)-2-phenoxyethanone | 1225061-41-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(4-(5-amino-6-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-5,6-dihydropyridin-1(2H)-yl)-2-phenoxyethanone
• 英文别名: 1-[4-[5-amino-6-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-3,6-dihydro-2H-pyridin-1-yl]-2-phenoxyethanone
• CAS: 1225061-41-5
• 化学式: C₂₅H₂₂N₆O₃
• 分子量: 454.488
• InChiKey: XHPBIYANSZNLPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE<br/>[FR] COMPOSÉS UTILES COMME INHIBITEURS DE L'ATR KINASE
  申请人：VERTEX PHARMA

  公开号：WO2010054398A1

  公开（公告）日：2010-05-14

  The present disclosure relates to pyrazine compounds of formula (I) wherein L, n, R1, and R2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.

  本公开涉及式(I)的吡嗪化合物，其中L、n、R1和R2如规范中所述。这些化合物可用作ATR蛋白激酶的抑制剂。本公开还涉及包含本公开的化合物的药用组合物；使用本公开的化合物治疗各种疾病、疾病和病况的方法；制备本公开的化合物的方法；制备本公开的化合物的中间体；以及在体外应用中使用这些化合物的方法，例如在生物和病理现象中研究激酶、介导这些激酶的细胞内信号转导途径的研究，以及新的激酶抑制剂的比较评估。
• COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
  申请人：Charrier Jean-Damien

  公开号：US20120040020A1

  公开（公告）日：2012-02-16

  The present disclosure relates to pyrazine compounds of formula I: wherein L, n, R 1 , and R 2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.

  本公开涉及式I的吡嗪化合物：其中L、n、R1和R2如规范所述。这些化合物可用作ATR蛋白激酶的抑制剂。本公开还涉及包含本公开化合物的药学上可接受的组合物；使用本公开化合物治疗各种疾病、障碍和病况的方法；制备本公开化合物的过程；制备本公开化合物的中间体；以及在体外应用中使用这些化合物的方法，例如研究生物和病理现象中的激酶、这些激酶介导的细胞内信号传导途径的研究以及新的激酶抑制剂的比较评估。
• US8410112B2
  申请人：——

  公开号：US8410112B2

  公开（公告）日：2013-04-02